Amedisys Financials

AMED Stock  USD 92.46  0.17  0.18%   
Based on the key indicators related to Amedisys' liquidity, profitability, solvency, and operating efficiency, Amedisys may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At present, Amedisys' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 402 M, whereas Accounts Payable is forecasted to decline to about 19 M. Key indicators impacting Amedisys' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.40.3838
Sufficiently Up
Very volatile
Current Ratio1.221.049
Fairly Up
Very volatile
The financial analysis of Amedisys is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Amedisys includes many different criteria found on its balance sheet. For example, investors should never minimize Amedisys' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Amedisys' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Amedisys.

Net Income

(9.26 Million)

With this module, you can analyze Amedisys financials for your investing period. You should be able to track the changes in Amedisys individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  
Understanding current and past Amedisys Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Amedisys' financial statements are interrelated, with each one affecting the others. For example, an increase in Amedisys' assets may result in an increase in income on the income statement.
Evaluating Amedisys' financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of Amedisys' profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the Amedisys' relative financial performance

Chance Of Distress

Less than 14

 
100  
 
Zero
Low
Amedisys has less than 14 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Amedisys stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, Amedisys' odds of distress score SHOULD NOT be confused with the real chance of Amedisys filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as Amedisys is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include Amedisys' liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More Info
The data published in Amedisys' official financial statements usually reflect Amedisys' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Amedisys. For example, before you start analyzing numbers published by Amedisys accountants, it's critical to develop an understanding of what Amedisys' liquidity, profitability, and earnings quality are in the context of the Health Care Providers & Services space in which it operates.
Please note, the presentation of Amedisys' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Amedisys' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Amedisys' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Amedisys. Please utilize our Beneish M Score to check the likelihood of Amedisys' management manipulating its earnings.

Amedisys Company Summary

Amedisys competes with Edwards Lifesciences, Spectral, Microbot Medical, Medigus, and EUDA Health. Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana. Amedisys operates under Medical Care Facilities classification in the United States and is traded on NASDAQ Exchange. It employs 21000 people.
Specialization
Health Care, Health Care Equipment & Services
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CIK Number0000896262
ISINUS0234361089
CUSIP023436108
RegionNorth America
LocationLouisiana; U.S.A
Business Address3854 American Way,
SectorHealth Care Providers & Services
IndustryHealth Care
BenchmarkNYSE Composite
Websitewww.amedisys.com
Phone225 292 2031
CurrencyUSD - US Dollar
You should never invest in Amedisys without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Amedisys Stock, because this is throwing your money away. Analyzing the key information contained in Amedisys' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Amedisys Key Financial Ratios

Generally speaking, Amedisys' financial ratios allow both analysts and investors to convert raw data from Amedisys' financial statements into concise, actionable information that can be used to evaluate the performance of Amedisys over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Amedisys reports annually and quarterly.

Amedisys Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets1.3B1.6B1.9B2.0B2.1B2.2B
Other Current Liab(3.1M)313.1M(3.4M)(20.1B)382.9M402.0M
Net Debt295.8M225.2M502.9M497.4M341.4M358.4M
Retained Earnings246.4M430.0M639.1M757.7M747.9M785.3M
Accounts Payable31.3M42.7M38.2M43.7M28.2M19.0M
Cash30.3M81.8M42.7M40.5M145.9M153.2M
Net Receivables237.6M255.1M275.0M296.8M328.2M344.6M
Inventory74.4M11.8M13.4M25.2M29.0M30.5M
Other Current Assets8.2M13.3M25.6M26.4M22.9M24.0M
Total Liab621.2M756.5M880.6M869.7M940.4M987.4M
Total Current Assets350.6M362.0M356.7M389.0M496.9M521.8M
Short Term Debt37.7M40.5M44.2M49.0M62.6M65.7M
Other Liab5.9M33.6M5.0M25.2M29.0M30.5M
Other Assets12K174.6M73.3M39.3M45.2M47.5M
Long Term Debt232.3M204.5M432.1M419.4M361.9M380.0M
Treasury Stock(251.2M)(319.1M)(435.9M)(461.2M)(415.1M)(394.3M)
Good Will658.5M932.7M1.2B1.3B1.2B1.3B
Intangible Assets64.7M74.2M111.2M101.2M102.7M64.1M
Net Tangible Assets(82.8M)(197.6M)(375.9M)(337.0M)(303.3M)(288.1M)
Long Term Debt Total232.3M204.5M432.1M419.4M482.3M506.4M

Amedisys Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Amedisys' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201920202021202220232024 (projected)
Interest Expense14.5M11.0M9.5M22.2M31.3M32.8M
Total Revenue2.0B2.1B2.2B2.2B2.2B2.3B
Gross Profit805.3M886.2M980.8M962.8M457.1M447.4M
Operating Income177.5M219.3M251.9M180.8M193.1M202.7M
Ebit177.5M219.3M251.9M180.8M193.1M202.7M
Ebitda240.7M294.0M329.9M256.4M216.9M227.8M
Cost Of Revenue1.2B1.2B1.2B1.3B1.8B1.9B
Net Income126.8M183.6M209.1M118.6M(9.7M)(9.3M)
Income Tax Expense42.5M25.6M70.1M42.5M50.6M53.1M
Income Before Tax170.4M210.8M280.2M160.2M39.6M45.7M
Minority Interest1.1M1.6M1.1M(910K)1.1M1.1M
Tax Provision42.5M25.6M70.1M42.5M50.2M42.3M
Interest Income78K292K49K178K2.5M2.6M
Net Interest Income(14.4M)(10.7M)(9.5M)(22.1M)(26.3M)(25.0M)

Amedisys Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Amedisys. It measures of how well Amedisys is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Amedisys brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Amedisys had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Amedisys has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201920202021202220232024 (projected)
Change To Inventory26.9M22.2M7.1M(2.0M)(1.8M)(1.9M)
Change In Cash76.3M(13.1M)(37.6M)8.4M84.1M88.3M
Free Cash Flow194.1M283.6M182.2M126.1M124.5M73.2M
Depreciation54.3M67.9M71.3M71.0M23.8M22.7M
Other Non Cash Items12.6M9.4M(29.9M)9.7M136.6M143.4M
Capital Expenditures7.9M5.3M6.7M7.2M12.7M17.5M
Net Income127.9M185.2M210.2M117.7M(9.7M)(9.3M)
End Period Cash Flow96.5M83.4M45.8M54.1M145.9M153.2M
Change Receivables(24.1M)2.1M(18.0M)(14.2M)(12.8M)(13.4M)
Net Borrowings56.0M(29.2M)230.2M(13.3M)(15.3M)(16.1M)
Dividends Paid3.2B3.6B4.0B1.6M(6.5M)(6.2M)
Change To Netincome50.2M5.8M38.7M48.7M43.8M72.1M
Investments(210K)17.0M(5.2M)(15.6M)35.2M37.0M

Amedisys Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Amedisys's current stock value. Our valuation model uses many indicators to compare Amedisys value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Amedisys competition to find correlations between indicators driving Amedisys's intrinsic value. More Info.
Amedisys is rated second in net income category among related companies. It is rated third in working capital category among related companies . At present, Amedisys' Net Loss is projected to increase significantly based on the last few years of reporting.. Comparative valuation analysis is a catch-all model that can be used if you cannot value Amedisys by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Amedisys' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Amedisys' earnings, one of the primary drivers of an investment's value.

Amedisys Systematic Risk

Amedisys' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Amedisys volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Amedisys correlated with the market. If Beta is less than 0 Amedisys generally moves in the opposite direction as compared to the market. If Amedisys Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Amedisys is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Amedisys is generally in the same direction as the market. If Beta > 1 Amedisys moves generally in the same direction as, but more than the movement of the benchmark.

About Amedisys Financials

What exactly are Amedisys Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Amedisys' income statement, its balance sheet, and the statement of cash flows. Potential Amedisys investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Amedisys investors may use each financial statement separately, they are all related. The changes in Amedisys's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Amedisys's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze Amedisys Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Amedisys is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Amedisys has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if Amedisys' financials are consistent with your investment objective using the following steps:
  • Review Amedisys' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand Amedisys' liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare Amedisys' financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Amedisys' stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.
Today, most investors in Amedisys Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Amedisys' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Amedisys growth as a starting point in their analysis.

Price Earnings To Growth Ratio

3.08

At present, Amedisys' Price Earnings To Growth Ratio is projected to slightly grow based on the last few years of reporting.

Amedisys March 28, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Amedisys help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Amedisys. We use our internally-developed statistical techniques to arrive at the intrinsic value of Amedisys based on widely used predictive technical indicators. In general, we focus on analyzing Amedisys Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Amedisys's daily price indicators and compare them against related drivers.
When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.
For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.
Note that the Amedisys information on this page should be used as a complementary analysis to other Amedisys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Complementary Tools for Amedisys Stock analysis

When running Amedisys' price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Equity Valuation
Check real value of public entities based on technical and fundamental data
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Is Amedisys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.40)
Earnings Share
(0.30)
Revenue Per Share
68.603
Quarterly Revenue Growth
0.016
Return On Assets
0.0598
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.